Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19.07.19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 10.09.19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19.07.19 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 23.07.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19.07.19 |
Paul Lammers
BRD | Director/Board Member | 66 | 19.07.19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 19.06.20 |
William McVicar
CHM | Chairman | 66 | 19.07.19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19.07.19 |
Tess Burleson
BRD | Director/Board Member | 57 | 19.07.19 |
David Arthur
CEO | Chief Executive Officer | 61 | 19.07.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 597 054 | 560 776 ( 93,92 %) | 0 | 93,92 % |
Unternehmenskontakt
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+25,83 % | 46,56 Mrd. | |
+45,38 % | 41,67 Mrd. | |
+0,69 % | 41,16 Mrd. | |
+30,52 % | 32,4 Mrd. | |
+22,30 % | 28,18 Mrd. | |
-6,35 % | 28,1 Mrd. | |
+49,25 % | 14,52 Mrd. | |
+49,18 % | 13,74 Mrd. | |
+3,45 % | 12,17 Mrd. |